Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set of challenges for both patients…
Browsing: Myeloproliferative Disease
The battle against polycythemia vera (PV), a rare and chronic form of blood cancer, has seen a transformative advancement with…
By: Abdulraheem Yacoub MD Date: October 25, 2023 In a prestigious medical conference hall filled with experts in the field of…
By: John Mascarenhas, MD Date: October 04, 2023 John Mascarenhas, MD, stands as a distinguished authority in the realm of…
By: Allen WilbanksDate: October 01, 2023 In a conference room filled with medical professionals and researchers, the audience leaned forward,…
By: Allen Wilbanks Date: September 29/2023 At the conference, Pankit expressed gratitude for another great talk, saying, “Thank you, Pankit…
By: Allen Wilbanks Date: September 28, 2023 Raajit Rampal MD. PhD, offered a glimpse of what the audience could expect.…
Prithvi Bose, an associate professor in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, focuses on…
Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A…
Myelodysplastic Syndromes Treatment Update for 2023 So briefly with regard to myelodysplastic syndromes MDS, I just wanted to discuss some…
iFrame is not supported! MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results…
Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis?…
iFrame is not supported! Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this…
Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis?…
iFrame is not supported! IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD,…
iFrame is not supported! IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD,…
IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD, FACP What is the…
iFrame is not supported! Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the…
Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the study of Pacritinib in…
iFrame is not supported! Momelotinib: Update On MOMENTUM Trial Dr. Gerds ASH 2022 By Aaron Gerds, MD What is the…
Momelotinib: Update On MOMENTUM Trial Dr. Gerds ASH 2022 By Aaron Gerds, MD What is the difference between the Momelotinib…
iFrame is not supported! Clonal Hematopoiesis: Myeloid Malignancy Prediction – ASH 2022 By LaChelle Weeks, MD, PhD What is clonal…
Clonal Hematopoiesis: Myeloid Malignancy Prediction – ASH 2022 By LaChelle Weeks, MD, PhD What is clonal hematopoiesis and why is…
Aaron T. Gerds, MD, MS, Associate Professor of Medicine, Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer…
Momelotinib Shows Promising JAK and ALK2 Inhabitation in Patients With Anemic Myelofibrosis: MOMENTUM Study It’s my pleasure today to discuss…
Srdan Verstovsek, MD, Ph.D., Professor, Department of Leukemia at MD Anderson Cancer Center. In this video, he speaks about Sierra…
Srdan Verstovsek, MD, Ph.D., Professor, Department of Leukemia at MD Anderson Cancer Center. In this video, he speaks about Sierra…
Ruben A. Mesa, MD, FACP from Mays Cancer Center, UT Health San Antonio Cancer Center speaks about the ASH 2021…
Ruben A. Mesa, MD, FACP from Mays Cancer Center, UT Health San Antonio Cancer Center speaks about the ASH 2021…
MarÃa DÃez Campelo, MD of the Universidad de Salamanca speaks about a Randomized phase 2 trial of pevonedistat plus azacitidine…
Mikkael Sekeres, MD @CleClinicMD @TakedaPharma FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic…
Earn CME: https://www.naccme.com/program/20-hemcovid-6 In this webcast, Drs. Joseph R. Mikhael and Jessica K. Altman discuss best practices for addressing current…
Aaron Gerds, MD of @CleClinicMD discusses the phase 2 study of luspatercept in patients with myelofibrosis-associated anemia
Aaron Gerds, MD of @CleClinicMD discusses the phase 2 study of luspatercept in patients with myelofibrosis-associated anemia
Aref Al-Kali MD Of The Mayo Clinic Discusses Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome,…
Aref Al-Kali MD Of The Mayo Clinic Discusses How To Use Drugs In Patients With Myeloid Disorders: Focusing On Azacitidine…
Dr. J.J. Kiladjian ASH 2018 Headline Research Studies
Ruxopeg Phase 1-2 Trial of Ruxolitinib and Pegasys in Patients with Myelofibrosis
Real World Risk Assessment and Treatment of patients with Myelofibrosis at Community Oncology Practices in the U.S.
Aziz Nazha MD of Cleveland Clinic discusses using Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning at ASH 2018
Aziz Nazha MD of Cleveland Clinic discusses the overview of his study of A Personalized Prediction Model for Outcomes after…
While myelodysplastic syndromes (MDS) represent a heterogeneous set of pathologies, a large proportion of MDS show similarity in somatic mutations.…
Many clinical trials are skewed towards a certain patient population, resulting in biased data. Here, Ruben Mesa, MD, of UT…
Symptom burden in patients with myeloproliferative neoplasms (MPNs), in the form of fatigue, night sweats and weight loss, can remain…
The treatment landscape for myeloproliferative neoplasms (MPNs) is constantly evolving, as Ruben Mesa, MD, of UT Health San Antonio Cancer…
Treatment of myeloproliferative neoplasms (MPNs) is expanding to include several exciting new therapies. We spoke to Claire Harrison, MD, FRCP,…
Claire Harrison, MD, FRCP, FRCPath, from Guy’s and St Thomas’ Hospital, London, UK, presented updates and results from the MAJIC…
Treating myelofibrosis is accompanied by several complications that must be considered, including thrombocytopenia and anemia. In this video, recorded at…
Overexpression of CD123 is associated with a number of hematological malignancies, including myelofibrosis and chronic myelomonocytic leukemia (CMML). Data was…